# **Complete Summary**

#### **GUIDELINE TITLE**

Evidence-based care guideline for anesthesia, analgesia and sedation following arterial switch operation.

# **BIBLIOGRAPHIC SOURCE(S)**

Cincinnati Children's Hospital Medical Center. Evidence based care guideline for anesthesia, analgesia and sedation following arterial switch operation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2006 Jan 10. 8 p. [16 references]

#### **GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for anesthesia, analgesia and sedation following arterial switch operation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2001 Jan 22. 8 p.

Once the guideline has been in place for four years, the development team reconvenes to explore the continued validity of the guideline. This phase can be initiated at any point that evidence indicates a critical change is needed.

## **COMPLETE SUMMARY CONTENT**

**SCOPE** 

METHODOLOGY - including Rating Scheme and Cost Analysis

RECOMMENDATIONS

EVIDENCE SUPPORTING THE RECOMMENDATIONS

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS QUALIFYING STATEMENTS

IMPLEMENTATION OF THE GUIDELINE

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IDENTIFYING INFORMATION AND AVAILABILITY

**DISCLAIMER** 

# **SCOPE**

# **DISEASE/CONDITION(S)**

Physiologic stress, pain, agitation, and discomfort following arterial switch operation

## **GUIDELINE CATEGORY**

Evaluation Treatment

## **CLINICAL SPECIALTY**

Anesthesiology Cardiology Critical Care Pediatrics Surgery

## **INTENDED USERS**

Advanced Practice Nurses Nurses Physician Assistants Physicians

# **GUIDELINE OBJECTIVE(S)**

To provide a clinical guideline for anesthesia, analgesia, and sedation following arterial switch operation

## **TARGET POPULATION**

These guidelines are intended primarily for use in neonates (age  $\leq$ 30 days) who have undergone an arterial switch operation (with or without ventricular septal defect closure).

The guidelines do <u>not</u> address all considerations needed to manage those with the following:

• Adverse/allergic reaction to morphine, fentanyl, lorazepam, or midazolam

## INTERVENTIONS AND PRACTICES CONSIDERED

#### **Assessment**

- 1. Assessment of hemodynamic stability as indicated by electrocardiographic monitoring, the mean arterial pressure (via arterial line), left atrial pressure (via transthoracic catheter), and urine output
- 2. Assessment of pain relief, patient comfort, and level of sedation, as indicated by behavioral assessment and absence of tachycardia or hypertension

## **Treatment**

1. Fentanyl infusion

- 2. Concurrent use of midazolam or lorazepam with the fentanyl infusion to ensure adequate sedation
- 3. Provision of adequate analgesia and sedation using as needed doses of morphine and midazolam once the fentanyl infusion has been discontinued

#### **MAJOR OUTCOMES CONSIDERED**

- Physiologic stress response to cardiac surgery
- Pain control
- Sedation
- Risk for adverse hemodynamic events
- Adverse effects of narcotics, such as respiratory depression
- Time to extubation
- Hemodynamic stability
- Length of stay in the Cardiac Intensive Care Unit (CICU)

## **METHODOLOGY**

# METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

# DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

To select evidence for critical appraisal by the group for the update of this guideline, the Medline, EmBase and the Cochrane databases were searched. Evidence from 2000 and before was verified for inclusion in the guidelines. Evidence from 2001 to January, 2006 was reviewed for relevance to the clinical topics/questions to generate an unrefined, "combined evidence" database using a search strategy focused on answering clinical questions relevant to anesthesia, analgesia, or sedation following arterial switch operations and employing a combination of Boolean searching on human-indexed thesaurus terms (MeSH headings using an OVID Medline interface) and "natural language" searching on searching on human-indexed thesaurus terms (MeSH headings using an OVID Medline interface) and "natural language" searching on words in the title, abstract, and indexing terms. The citations were reduced by: eliminating duplicates, review articles, non-English articles, and adult articles. The resulting abstracts were reviewed by a methodologist to eliminate low quality and irrelevant citations. During the course of the guideline development, additional clinical questions were generated and subjected to the search process, and some relevant review articles were identified. April, 2000 was the last date for which literature was reviewed for the previous version of this quideline. The details of that review strategy are not documented. However, all previous citations were reviewed for appropriateness to this revision.

A search using the above criteria was conducted for dates of January, 2006 through July, 2006. No relevant articles were found that would require changes to the January, 2006 version of the recommendations.

# **NUMBER OF SOURCE DOCUMENTS**

Not stated

# METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

#### RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

# METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

## **DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not stated

## METHODS USED TO FORMULATE THE RECOMMENDATIONS

**Expert Consensus** 

# DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

The recommendations contained in this guideline were formulated by an interdisciplinary working group which performed systematic and critical literature reviews, using a grading scale, and examined current local clinical practices.

Recommendations have been formulated by a consensus process directed by best evidence, patient and family preference and clinical expertise. During formulation of these guidelines, the team members have remained cognizant of controversies and disagreements over the management of these patients. They have tried to resolve controversial issues by consensus where possible and, when not possible, to offer optional approaches to care in the form of information that includes best supporting evidence of efficacy for alternative choices.

# RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

# **COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

# **METHOD OF GUIDELINE VALIDATION**

Internal Peer Review

## **DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Experience with the implementation of earlier publications of this guideline has provided information which has been incorporated into this revision.

The guidelines have been reviewed by clinical experts not involved in the development process, senior management, and other individuals as appropriate to their intended purposes. The guideline is based in part on three independent reviews performed by members of Evidence-Based Care Group of Health Policy & Clinical Effectiveness at Cincinnati Children's Hospital and Medical Center (CCHMC) using AGREE criteria (Appraisal of Guidelines for Research and Evaluation).

## **RECOMMENDATIONS**

#### **MAJOR RECOMMENDATIONS**

Each recommendation is followed by evidence grades identifying the type of supporting evidence. Definitions of the evidence grades are presented at the end of the "Major Recommendations" field.

#### **Clinical Assessments**

- 1. It is recommended that hemodynamic stability be maintained as indicated by mean arterial pressure >45, left atrial pressure <15, and urine output >1cc/kg/hr. Physical exam should indicate adequate perfusion.
  - **Note 1**: Continuous monitoring of electrocardiogram (ECG) and arterial blood pressure via an arterial line is recommended (Local Expert Consensus [E]).
  - **Note 2**: Continuous monitoring of left atrial pressure with a transthoracic catheter is recommended (Local Expert Consensus [E]).
- 2. It is recommended that adequate pain relief is provided as indicated by behavioral assessment and the absence of otherwise unexplained tachycardia or hypertension.
- 3. It is recommended that patient comfort and sedation be maintained as indicated by behavioral assessment. The patient should not be at risk for inadvertent self-removal of lines and/or tubes.

## **Treatment Recommendations**

4. It is recommended that a fentanyl infusion at 10 micrograms/kg/hr be started on all post-operative arterial switch patients and maintained for at least 6 hours. The infusion should be discontinued if the patient has had no signs or symptoms of low cardiac output (mean arterial pressure <45, urine output <1 cc/kg/hr, persistent base deficit >-4 despite correction with sodium bicarbonate [NaHCO<sub>3</sub>] or increase in lactate level >0.5 mg/dl/hr) and is therefore considered a good candidate for extubation in the next 24 hours.

**Note 1**: A continuous infusion of high-dose fentanyl is maintained to blunt the physiologic stress response that occurs as a consequence of cardiac surgery (Anand, Hansen, & Hickey, 1990 [D]; Anand & Hickey, 1992 [B]). Because cardiac output decreases for at least the first 6 hours following cardiopulmonary bypass, it is recommended that the infusion be continued for at least this length of time (Wernovsky et al., 1995 [A]).

**Note 2**: Because of the redistribution of fentanyl into lipid tissue, long-term infusion may result in prolongation of side effects such as apnea well beyond termination of the infusion (Cincinnati Children's Hospital Medical Center Formulary, 2006)[X]. Therefore, once pain management, rather than hemodynamic stability, becomes the primary reason for narcotic use, it is desirable to use bolus dosing of a less lipophilic agent such as morphine and to discontinue the fentanyl infusion (Local Expert Consensus [E]).

**Note 3**: Ongoing metabolic acidosis caused by the continued production of lactic acid has been associated with a poor outcome following cardiac surgery in infants and children. (Charpie et al., 2000 [C]; Munoz et al., 2000 [C]).

5. It is recommended that midazolam (0.1 mg/kg/dose every 1 to 2 hours) or lorazepam (0.1 mg/kg/dose every 6 to 8 hours) be given concurrently with the fentanyl infusion to ensure adequate sedation in addition to anesthesia/analgesia.

**Note**: Because of the variability in neonatal response to fentanyl and because of rapid development of tolerance to its sedative effects (in contrast to respiratory depressant effects), additional use of benzodiazepines is often necessary to maintain adequate sedation (Arnold et al., 1991 [C]).

6. It is recommended that adequate analysesia and sedation be provided using as needed doses of morphine (0.1 mg/kg/dose) and midazolam (0.1 mg/kg/dose) once the fentanyl infusion has been discontinued.

**Note**: The longer half-life of morphine makes it a better choice for intermittent dosing than fentanyl. The histamine release associated with morphine should be well tolerated hemodynamically by patients who are otherwise stable 6 hours after cardiopulmonary bypass (Saarenmaa et al., 1999 [A]; Saarenmaa, Neuvonen, & Fellman, 2000 [C]; Santeiro et al., 1997 [C]; Hamon et al., 1996 [C]; Katz & Kelly, 1993 [C]; Arnold et al., 1991 [C]; Murat et al., 1988 [C]).

#### Definitions:

# **Evidence Based Grading Scale**

M: Meta-analysis or systematic review

A: Randomized controlled trial: large sample

B: Randomized controlled trial: small sample

C: Prospective trial or large case series

D: Retrospective analysis

S: Review article

- O: Other evidence
- E: Expert opinion or consensus
- F: Basic laboratory research
- L: Legal requirement
- Q: Decision analysis
- X: No evidence

# **CLINICAL ALGORITHM(S)**

None provided

# **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

#### REFERENCES SUPPORTING THE RECOMMENDATIONS

References open in a new window

#### TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of evidence is identified and classified for each recommendation (see "Major Recommendations") using the following scheme:

- M: Meta-analysis or systematic review
- A: Randomized controlled trial: large sample
- B: Randomized controlled trial: small sample
- C: Prospective trial or large case series
- D: Retrospective analysis
- S: Review article
- O: Other evidence
- E: Expert opinion or consensus
- F: Basic laboratory research
- L: Legal requirement
- Q: Decision analysis
- X: No evidence

# BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

# **POTENTIAL BENEFITS**

- Blunting of physiologic stress response to cardiac surgery
- Pain control
- Sedation that provides comfort and safety
- Decreased risk for adverse hemodynamic events

# **POTENTIAL HARMS**

- Respiratory depression associated with high-dose narcotic use
- Because of the redistribution of fentanyl into lipid tissue, long-term infusion may result in prolongation of side effects such as apnea well beyond termination of the infusion.

# **QUALIFYING STATEMENTS**

# **QUALIFYING STATEMENTS**

- In developing this guideline, the working group recognizes the paucity of large-scale studies with direct bearing on this particular focus population. The specific recommendations in this guideline are drawn from directly applicable studies where possible, but are largely extrapolated from smaller studies and from studies more indirectly related to the present issues.
- These recommendations result from review of literature and practices current at the time of their formulations. This protocol does not preclude using care modalities proven efficacious in studies published subsequent to the current revision of this document. This document is not intended to impose standards of care preventing selective variances from the guidelines to meet the specific and unique requirements of individual patients. Adherence to this pathway is voluntary. The physician in light of the individual circumstances presented by the patient must make the ultimate judgment regarding the priority of any specific procedure.

## **IMPLEMENTATION OF THE GUIDELINE**

#### **DESCRIPTION OF IMPLEMENTATION STRATEGY**

Appropriate companion documents have been developed to assist in the effective dissemination and implementation of the guideline.

#### **IMPLEMENTATION TOOLS**

Foreign Language Translations Patient Resources

For information about <u>availability</u>, see the "Availability of Companion Documents" and "Patient Resources" fields below.

# INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

# **IOM CARE NEED**

**Getting Better** 

## **IOM DOMAIN**

Effectiveness Patient-centeredness

# **IDENTIFYING INFORMATION AND AVAILABILITY**

# **BIBLIOGRAPHIC SOURCE(S)**

Cincinnati Children's Hospital Medical Center. Evidence based care guideline for anesthesia, analgesia and sedation following arterial switch operation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2006 Jan 10. 8 p. [16 references]

#### **ADAPTATION**

Not applicable: The guideline was not adapted from another source.

#### **DATE RELEASED**

2001 Jan 22 (revised 2006 Jan 1)

# **GUIDELINE DEVELOPER(S)**

Cincinnati Children's Hospital Medical Center - Hospital/Medical Center

# **SOURCE(S) OF FUNDING**

Cincinnati Children's Hospital Medical Center

## **GUIDELINE COMMITTEE**

Cardiac Guideline Development Team 2006

## **COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE**

Cincinnati Children's Hospital Medical Center Physicians: Peter Manning, MD, Cardiac Surgery; Catherine Dent, MD, Cardiac Intensive Care; William Border, MD, Cardiology; James Spaeth MD, Anesthesia; Michael Alice Moga, MD, Cardiology/Fellow

Patient Services: Karen Uzark, PhD, CPNP, Cardiology; Susan Ryckman, MS, CPNP, Cardiac Services; Betsy Adler, MS, PNP, Cardiac Surgery; Melissa Magness, RN, Cardiac ICU; Tammy Lingsch, RN, A6 Central; Cynthia Wedekind, Pharm D, Clinical Pharmacy; Jenni Raake, RRT, Respiratory Care; Shawna Kirkendall, RN, Manager, A 6 Central

Division of Health Policy & Clinical Effectiveness Support: Eloise Clark, MPH; Danette Stanko, MA, MPH, Epidemiologist; Kate Rich, Lead Decision Support Analyst; Carol Frese, RN, Medical Reviewer; Eduardo Mendez, RN, MPH, Dir. Evidence-Based Care; Edward Donovan, MD, Medical Director, Clinical Effectiveness

#### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

This guideline was developed without external funding.

# **GUIDELINE STATUS**

This is the current release of the guideline.

This guideline updates a previous version: Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for anesthesia, analgesia and sedation following arterial switch operation. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2001 Jan 22. 8 p.

Once the guideline has been in place for four years, the development team reconvenes to explore the continued validity of the guideline. This phase can be initiated at any point that evidence indicates a critical change is needed.

#### **GUIDELINE AVAILABILITY**

Electronic copies: Available in Portable Document Format (PDF) from the Cincinnati Children's Hospital Medical Center Web site.

For information regarding the full-text guideline, print copies, or evidence based practice support services contact the Children's Hospital Medical Center Health Policy and Clinical Effectiveness Department at <a href="https://example.com/hybrideness-nc-rule-new-months.com/hybrideness-nc-rule-n

## **AVAILABILITY OF COMPANION DOCUMENTS**

None available

## **PATIENT RESOURCES**

The following is available:

 Going home after heart surgery. Home care. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2004 Dec. 1 p. Available in English and Spanish from the Cincinnati Children's Hospital Medical Center Web site.

Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.

#### **NGC STATUS**

This NGC summary was completed by ECRI on March 11, 2004. This NGC summary was updated by ECRI on November 29, 2006. The updated information was verified by the guideline developer on December 19, 2006.

#### COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

Copies of <u>Cincinnati Children's Hospital Medical Center (CCHMC)</u> Evidence-Based Clinical Practice Guidelines (EBCG) are available online and may be distributed by any organization for the global purpose of improving child health outcomes. Examples of approved uses of CCHMC's EBCG include the following:

- Copies may be provided to anyone involved in the organization's process for developing and implementing evidence-based care guidelines.
- Hyperlinks to the CCHMC website may be placed on the organization's website.
- The EBCG may be adopted or adapted for use within the organization, provided that CCHMC receives appropriate attribution on all written or electronic documents.
- Copies may be provided to patients and the clinicians who manage their care.

Notification of CCHMC at <a href="https://example.com"><u>HPCEInfo@cchmc.org</u></a> for any EBCG adopted, adapted, implemented or hyperlinked to by a given organization and/or user, is appreciated.

## DISCLAIMER

#### NGC DISCLAIMER

The National Guideline Clearinghouse<sup>™</sup> (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href="http://www.quideline.gov/about/inclusion.aspx">http://www.quideline.gov/about/inclusion.aspx</a>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the quideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/22/2008

